We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Immunovant Inc
17 own
6 watching
Current Price
$17.6
$-0.87
(-4.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
2,052.41M
52-Week High
20.24
52-Week Low
3.145
Average Volume
0.72M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,052.41M52-Week High20.2452-Week Low3.145Average Volume0.72MDividend Yield--P/E Ratio--What does the Immunovant Inc do?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More
How much money does Immunovant Inc make?
News & Events about Immunovant Inc.
Ticker Report
11days ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) insider Julia G. Butchko sold 60,490 shares of the stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $16.79, for a total value of $1,015,627.10. Following the transaction, the insider now ...
Globe Newswire
2 months ago
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at ...
Globe Newswire
2 months ago
IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiledNew development programs for batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves disease announcedPhase 3 trials of batoclimab in myasthenia ...
PR Newswire
3 months ago
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing PR Newswire PALM BEACH, Fl, Oct. 5, 2022 PALM BEACH, Fl, Oct. 5, 2022...
Globe Newswire
3 months ago
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an ...
Frequently Asked Questions
Frequently Asked Questions
What is Immunovant Inc share price today?
Can Indians buy Immunovant Inc shares?
How can I buy Immunovant Inc shares from India?
Can Fractional shares of Immunovant Inc be purchased?
What are the documents required to start investing in Immunovant Inc stocks?
What is today’s traded volume of Immunovant Inc?
What is today’s market capitalisation of Immunovant Inc?
What is the 52-Week High and Low Range of Immunovant Inc?
What percentage is Immunovant Inc down from its 52-Week High?
What percentage is Immunovant Inc up from its 52-Week Low?
Current Price
$17.6
$-0.87
(-4.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.